Rodrigo Sánchez-Bayona, Medical Oncologist at 12 de Octubre University Hospital, shared on X:
“New paper on the management of HR+/HER2- early breast cancer in the genomic era!
Here are the real-world outcomes on how intermediate-risk (i-ROR) PAM50 patients fit into the new landscape of adjuvant CDK4/6 inhibitors.
The Genomic ‘Grey Zone’
While treatment decisions are relatively straightforward for high and low Risk of Recurrence (ROR) extremes, deciding on adjuvant strategies for the i-ROR group remains challenging.
Favorable Prognosis, But Relapses Occur
A real-world cohort of 212 i-ROR patients demonstrated an excellent 5-year RFS of >96%. However, relapses still happen, predominantly in patients who are Luminal A (72.7%), node-negative (63.6%), and Cht-naive (90.9%).
Adjuvant CDK4/6i Eligibility
When applying recent trial criteria to this i-ROR cohort, 44.3% of patients were eligible for NATALEE (ribociclib) and 14.6% were eligible for monarchE (abemaciclib).
In total, nearly half (48.6%) of these intermediate-risk patients met the criteria for at least one adjuvant iCDK4/6. This highlights the need to refine risk stratification and carefully consider adjuvant systemic therapies, like iCDK4/6, even when genomic scores are intermediate.
And this work was made during a Clinical Unit Visit Fellowship of Dr Maria Illia (from Argentina) at our Institution Hospital Universitario 12 de Octubre thanks to ESMO.”
Title: Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors
Authors: Santiago Terán, María Illia, María Carla Quevedo, Marina López Moreno, Manuel Alva Bianchi, Laura Lema, Cristina González, Pablo Tolosa, Ainhoa Madariaga, Luis Manso, Yolanda Ruano, Lucía Parrilla, María Ángeles Cobos, Eva Ciruelos, Rodrigo Sánchez-Bayona
Read the full article.
